What is Cornerstone Robotics?
Founded in 2019, Cornerstone Robotics (CSR) has established itself as a pivotal innovator in the field of surgical robotics. The company specializes in the development and deployment of cutting-edge robotic systems designed to improve surgical precision, efficiency, and patient outcomes. By integrating multidisciplinary expertise from clinical professionals and robotics engineers, CSR addresses critical gaps in modern healthcare delivery.
The company maintains a robust global presence with strategic hubs in Hong Kong, Shenzhen, Beijing, Shanghai, London, and Portsmouth. This geographic diversity allows Cornerstone Robotics to tap into international talent pools and navigate complex regulatory environments, positioning it as a leader in the medical device sector. Its core mission remains the democratization of high-quality surgical care through technological advancement.
How much funding has Cornerstone Robotics raised?
Cornerstone Robotics has raised a total of $348.3M across 3 funding rounds:
Series B
$78.3M
Series C
$70M
Other Financing Round
$200M
Series B (2021): $78.3M with participation from Gaorong Capital, Eli Lilly, Meituan, and New World
Series C (2025): $70M led by Alpha JWC Ventures, EQT, ITVF - Innovation and Technology Venture Fund, eGarden, and Qiming Venture Partners
Other Financing Round (2025): $200M supported by Gaorong Capital and Qiming Venture Partners
Key Investors in Cornerstone Robotics
Gaorong Capital
Gaorong Capital, founded in 2014 and headquartered in China, is a venture capital firm that specializes in investments.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that focuses on investing in innovative companies across various sectors, including technology, healthcare, and artificial intelligence.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines.
What's next for Cornerstone Robotics?
With the successful closure of this latest funding round, Cornerstone Robotics is expected to prioritize the commercialization of its next-generation surgical platforms. The strategic allocation of these funds will likely focus on scaling manufacturing capacity, accelerating clinical trials, and deepening market penetration in both established and emerging healthcare markets.
Furthermore, the company is well-positioned to leverage its partnerships with institutional investors to foster collaborative innovation. As it continues to refine its robotic systems, the focus will shift toward long-term sustainability and the integration of artificial intelligence to further enhance surgical workflows. This growth trajectory suggests that Cornerstone Robotics is preparing for a potential future public offering or further strategic consolidation within the medical technology ecosystem.
